Insulin Glargine U-100 vs U-300
Pharmacokinetic and pharmacodynamic comparison of insulin glargine at 100 U/mL and 300 U/mL concentrations, covering onset, peak, duration, and clinical implications.
Insulin Glargine U-100 vs U-300
Introduction
Insulin glargine is a long-acting basal insulin analogue produced by recombinant DNA technology. It is available in two concentrations: U-100 (100 units/mL, marketed as Lantus) and U-300 (300 units/mL, marketed as Toujeo). The threefold concentration difference produces clinically meaningful pharmacokinetic and pharmacodynamic distinctions that influence dosing, injection volume, and glycemic control profiles.
Molecular Basis of Concentration Effects
Precipitation Mechanism
Insulin glargine precipitates at physiological pH following subcutaneous injection. The precipitation behavior differs between formulations:
- U-100: Forms a soluble depot that gradually releases insulin monomers. The lower concentration produces a smaller subcutaneous depot volume per unit.
- U-300: Forms a more compact, less soluble depot due to higher local concentration. The reduced surface area-to-volume ratio slows dissolution and absorption.
The pI of insulin glargine is approximately 6.7. At subcutaneous pH (~7.4), glargine exists as a microprecipitate that slowly dissociates into monomers for systemic absorption.
Depot Characteristics
| Parameter | U-100 | U-300 |
|---|---|---|
| Injection volume (40 U) | 0.4 mL | 0.13 mL |
| Depot surface area | Higher | Lower (by ~50%) |
| Precipitation rate | Faster | Slower |
| Monomer release | Faster | Slower |
Pharmacokinetic Profile
Absorption and Onset
Both formulations exhibit relatively flat pharmacokinetic profiles compared to NPH insulin, but with distinct absorption kinetics:
- U-100 onset: 1–2 hours after subcutaneous injection
- U-300 onset: 2–6 hours after subcutaneous injection (slower due to reduced depot surface area)
Peak and Duration
| Parameter | U-100 | U-300 |
|---|---|---|
| Time to peak concentration | 8–12 hours | 12–18 hours |
| Peak-to-trough ratio | Moderate | Lower (flatter) |
| Duration of action | Up to 24 hours | Up to 36 hours |
| Steady-state achievement | 2–4 days | 3–5 days |
The prolonged duration of U-300 permits more stable basal insulin coverage and may reduce nocturnal hypoglycemia risk.
Bioavailability
Relative bioavailability of U-300 compared to U-100 is approximately 87% at equal unit doses, reflecting slower but more complete absorption from the compact depot.
Pharmacodynamic Profile
Glucose-Lowering Effect
Clinical studies demonstrate equivalent HbA1c reduction between formulations at matched doses:
- U-100: Mean HbA1c reduction of 1.0–1.5% from baseline
- U-300: Mean HbA1c reduction of 1.0–1.5% from baseline
The primary difference lies in the shape of the glucose-lowering curve rather than total effect:
- U-100 produces a more pronounced early glucose-lowering effect (first 12 hours)
- U-300 distributes glucose-lowering more evenly across 24–36 hours
Glucose Infusion Rate (GIR) Studies
Hyperinsulinemic-euglycemic clamp studies reveal:
- U-100 GIR profile: Higher early GIR, declining after 16–20 hours
- U-300 GIR profile: Lower early GIR, sustained over 24–36 hours
- GIR variability: U-300 demonstrates lower within-subject variability (coefficient of variation ~20% vs ~30% for U-100)
Clinical Efficacy
Glycemic Control
Head-to-head trials demonstrate:
- Non-inferior HbA1c reduction: U-300 achieves comparable glycemic control to U-100 at higher unit doses
- Time in range (70–180 mg/dL): U-300 improves time in range by 5–10% in some studies
- Fasting glucose: Both achieve similar fasting glucose targets
Hypoglycemia Risk
The most clinically significant difference is hypoglycemia:
| Hypoglycemia Type | U-100 | U-300 |
|---|---|---|
| Nocturnal (confirmed) | Higher incidence | ~25–30% lower |
| Severe | Similar | Similar |
| Overall symptomatic | Higher | Lower |
| Time to first hypoglycemia | Earlier | Delayed |
The reduced nocturnal hypoglycemia with U-300 is attributed to the flatter pharmacokinetic profile and reduced peak effect.
Dosing Considerations
Conversion
When switching from U-100 to U-300:
- Starting dose: Reduce by approximately 20% (U-300 is more potent per unit due to prolonged action)
- Titration: Adjust based on fasting glucose and hypoglycemia events
- Maximum daily dose: U-300 permits higher unit doses in a single injection due to reduced volume
Injection Volume
The threefold concentration advantage of U-300 reduces injection volume:
| Dose | U-100 Volume | U-300 Volume |
|---|---|---|
| 20 U | 0.20 mL | 0.07 mL |
| 40 U | 0.40 mL | 0.13 mL |
| 80 U | 0.80 mL | 0.27 mL |
| 100 U | 1.00 mL | 0.33 mL |
Reduced injection volume improves patient comfort and injection site tolerance, particularly at higher doses.
Pen Device Compatibility
- U-100: Standard insulin pens (KwikPen, Solostar)
- U-300: Dedicated Toujeo pen ( SoloStar) with 0.5 mL cartridge
- Pens are NOT interchangeable between concentrations
Safety Profile
Injection Site Reactions
Both formulations have comparable injection site reaction rates (~2–5%). U-300 may produce less lipohypertrophy due to smaller depot volume, though long-term data are limited.
Immunogenicity
Anti-insulin antibody formation is comparable between formulations. Both are produced by recombinant technology with high purity (>98% insulin glargine).
Allergy
True allergy to insulin glargine is rare (<1% of patients). Cross-reactivity between U-100 and U-300 is expected due to identical amino acid sequence.
Storage and Handling
| Parameter | U-100 | U-300 |
|---|---|---|
| Unopened (2–8°C) | 24 months | 24 months |
| In-use (room temp) | 28 days | 28 days |
| Maximum temp | 25°C | 25°C |
| Protect from light | Yes | Yes |
Conclusion
Insulin glargine U-100 and U-300 represent the same molecule at different concentrations, yet produce clinically distinct pharmacokinetic profiles. U-300’s flatter, more prolonged action reduces nocturnal hypoglycemia risk and permits lower injection volumes, making it advantageous for patients requiring higher basal insulin doses or experiencing nocturnal hypoglycemia. U-100 remains appropriate for patients requiring standard basal insulin coverage with well-established efficacy and safety data spanning over two decades.